Sumitomo Pharma America, INC. (Formerly Sunovion Pharmaceuticals INC.)

Based in MA

🤖

AI Overview

With $7.5M in lobbying spend across 25 quarterly filings, Sumitomo Pharma America, INC. (Formerly Sunovion Pharmaceuticals INC.) is one of the biggest lobbying spenders in Washington. Their lobbying covers 1 issue area. Active from 2018 to 2024.

$7.5M
Total Spend
7
Years Active
1
Firms Hired
3
Lobbyists Deployed
1
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2018$1.3M
2019$1.3M
2020$1.1M
2021$1.1M
2022$1.3M
2023$1.1M
2024$210K

Issues Lobbied

Lobbying Firms

Lobbyists

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues

  • Discussions regarding protected classes reform
  • Part D proposed rule and LIS co-pays
  • Part B Payment reform
  • Massachusetts 1115 Medicaid waiver amendment
  • FDA Regulatory Review
  • Opioid Substance Abuse legi
  • Discussions regarding protected classes reform
  • Part B drug coverage and Payment reform
  • Massachusetts 1115 Medicaid waiver amendment
  • FDA Regulatory Review
  • Opioid Substance Abuse legislation
  • Medicare Pa
  • Discussions regarding protected classes reform, Medicare Part D
  • Part B drug coverage and Payment reform
  • Opioid Substance Abuse legislation
  • Medicare Part D Coverage Gap provisions in Bipartisan Budget
  • Discussions regarding protected classes reform, Medicare Part D
  • Part B drug coverage and Payment reform; international pricing index model
  • Medicare Part D Coverage Gap provisions in Bipartisan Budget
  • Discussions regarding protected classes reform, Medicare Part D
  • Part B drug coverage and Payment reform; international pricing index model
  • Medicare Part D Negotiation/Non-Interference Repeal Bills
  • Pri

Related Analysis

Related Investigations

Similar Clients

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.